D. Bradley Woodward

Dulaglutide versus insulin glargine in patients with type 2 diabetes and moderate-to-severe chronic kidney disease (AWARD-7): a multicentre, open-label, randomised trial

Mark Lakshmanan, Brian Rayner, Robert S. Busch et al. · The Lancet Diabetes & Endocrinology · 2018 · 635 citations

Medicine, Endocrinology, Pharmacotherapy +11

Dulaglutide as add-on therapy to SGLT2 inhibitors in patients with inadequately controlled type 2 diabetes (AWARD-10): a 24-week, randomised, double-blind, placebo-controlled trial

Bernhard Ludvik, Juan P. Frías, Francisco J. Tinahones et al. · The Lancet Diabetes & Endocrinology · 2018 · 261 citations · Full text

Medicine, Endocrinology, Pharmacology +16

Placebo‐controlled, randomized trial of the addition of once‐weekly glucagon‐like peptide‐1 receptor agonist dulaglutide to titrated daily insulin glargine in patients with type 2 diabetes ( <scp>AWARD</scp> ‐9)

Paolo Pozzilli, Paul Norwood, Esteban Jódar et al. · Diabetes Obesity and Metabolism · 2017 · 134 citations · Full text

Medicine, Pharmacology, Pharmacotherapy +17

Troponin-I as a prognosticator of mortality in severe sepsis patients

Jijo John, D. Bradley Woodward, Yanping Wang et al. · Journal of Critical Care · 2010 · 98 citations

Veterinary Medicine, Internal Medicine, Critical Care Medicine +11

Biomarker response to drotrecogin alfa (activated) in children with severe sepsis

Heidi J. Dalton, Joseph A. Carcillo, D. Bradley Woodward et al. · Pediatric Critical Care Medicine · 2012 · 17 citations

Veterinary Medicine, Pediatrics, Pharmacology +17